Fig. 3From: Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and consClinical trials based on tumor immunotherapy using immune checkpoint inhibitors (ICIs) registered in ClinicalTrials.gov (November 2021). The schematic illustrates clinical trials using ICIs depending on the study phase (A), study status (B), conditions (C), and agents (D) in cancer patientsBack to article page